Targeted nucleic acid delivery into tumors: new avenues for cancer therapy - PubMed (original) (raw)

Review

Targeted nucleic acid delivery into tumors: new avenues for cancer therapy

Ernst Wagner et al. Biomed Pharmacother. 2004 Apr.

Abstract

Unique properties of tumors, such as abnormalities in the cell cycle and apoptosis, migration and metastasis, neoangiogenesis or unique antigen profiles are targets for therapeutic anti-cancer strategies. Beyond the selection of such strategies, additional specificity for the targeted tumor tissue can be accomplished in cancer gene therapy in several ways. Upon systemic administration, appropriately packaged therapeutic nucleic acid may be preferentially transported into the tumor tissue (targeted delivery); formulation can mediate the intracellular uptake of the nucleic acid into the nucleus of target cells only (transductional targeting); and/or the use of specific promotor/enhancer elements can restrict transcription of therapeutic genes to the target cells only (transcriptional targeting). Options for physical and biological targeting of nucleic acid formulations into tumors and therapeutic approaches are reviewed.

PubMed Disclaimer

Similar articles

• Targeting strategies in cancer gene therapy.
  Wang JH, Liu XY. Wang JH, et al. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Apr;35(4):311-6. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003. PMID: 12673383 Review.
• Nanoparticle and targeted systems for cancer therapy.
  Brannon-Peppas L, Blanchette JO. Brannon-Peppas L, et al. Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59. doi: 10.1016/j.addr.2004.02.014. Adv Drug Deliv Rev. 2004. PMID: 15350294 Review.
• Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.
  Yamada Y, Harashima H. Yamada Y, et al. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1439-62. doi: 10.1016/j.addr.2008.04.016. Epub 2008 Jul 4. Adv Drug Deliv Rev. 2008. PMID: 18655816 Review.
• Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
  Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ. Brumlik MJ, et al. Expert Opin Drug Deliv. 2008 Jan;5(1):87-103. doi: 10.1517/17425247.5.1.87. Expert Opin Drug Deliv. 2008. PMID: 18095930 Review.
• Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
  Dorer DE, Nettelbeck DM. Dorer DE, et al. Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):554-71. doi: 10.1016/j.addr.2009.03.013. Epub 2009 Apr 23. Adv Drug Deliv Rev. 2009. PMID: 19394376 Review.

Cited by

• Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency.
  Melo ARDS, de Macêdo LS, Invenção MDCV, de Moura IA, da Gama MATM, de Melo CML, Silva AJD, Batista MVA, Freitas AC. Melo ARDS, et al. Genes (Basel). 2022 Dec 4;13(12):2287. doi: 10.3390/genes13122287. Genes (Basel). 2022. PMID: 36553554 Free PMC article. Review.
• High throughput optimization of stem cell microenvironments.
  Yang F, Mei Y, Langer R, Anderson DG. Yang F, et al. Comb Chem High Throughput Screen. 2009 Jul;12(6):554-61. doi: 10.2174/138620709788681916. Comb Chem High Throughput Screen. 2009. PMID: 19601753 Free PMC article. Review.
• Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.
  Aigner A. Aigner A. J Biomed Biotechnol. 2006;2006(4):71659. doi: 10.1155/JBB/2006/71659. J Biomed Biotechnol. 2006. PMID: 17057369 Free PMC article.
• Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use.
  Wu SY, Putral LN, Liang M, Chang HI, Davies NM, McMillan NA. Wu SY, et al. Pharm Res. 2009 Mar;26(3):512-22. doi: 10.1007/s11095-008-9766-1. Epub 2008 Nov 21. Pharm Res. 2009. PMID: 19023647

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information